A very rare cause of markedly elevated CA 19–9: Glucagon-like peptide-1 receptor agonists

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & metabolism Pub Date : 2024-09-11 DOI:10.1016/j.diabet.2024.101578

Rongyue Liang , Zhifang Fu , Long Chen , Shuang Zhou , Hongmei Jiao

{"title":"A very rare cause of markedly elevated CA 19–9: Glucagon-like peptide-1 receptor agonists","authors":"Rongyue Liang , Zhifang Fu , Long Chen , Shuang Zhou , Hongmei Jiao","doi":"10.1016/j.diabet.2024.101578","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-RAs) are commonly used to treat type 2 diabetes mellitus (T2DM). Various adverse reactions have been gradually reported. This case presents a rare phenomenon in which a GLP1-RA caused a marked elevation in carbohydrate antigen 19–9(CA 19–9) without evidence of a tumor.</p></div><div><h3>Methods</h3><p>A mixed-methods approach was utilized, incorporating medical history obtained from regular outpatient consultations and follow-up visits, along with ancillary examinations derived from laboratory tests and imaging.</p></div><div><h3>Results</h3><p>The use of a GLP1-RA for treating T2DM resulted in an increase in CA 19–9 without evidence of a tumor, which gradually normalized after discontinuation of the drug.</p></div><div><h3>Conclusion</h3><p>GLP1-RAs may lead to elevated levels of tumor markers during the treatment of T2DM, necessitating monitoring during therapy. Antidiabetic management should be adjusted on an individual basis as needed.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363624000703","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-RAs) are commonly used to treat type 2 diabetes mellitus (T2DM). Various adverse reactions have been gradually reported. This case presents a rare phenomenon in which a GLP1-RA caused a marked elevation in carbohydrate antigen 19–9(CA 19–9) without evidence of a tumor.

Methods

A mixed-methods approach was utilized, incorporating medical history obtained from regular outpatient consultations and follow-up visits, along with ancillary examinations derived from laboratory tests and imaging.

Results

The use of a GLP1-RA for treating T2DM resulted in an increase in CA 19–9 without evidence of a tumor, which gradually normalized after discontinuation of the drug.

Conclusion

GLP1-RAs may lead to elevated levels of tumor markers during the treatment of T2DM, necessitating monitoring during therapy. Antidiabetic management should be adjusted on an individual basis as needed.

查看原文本刊更多论文

导致 CA 19-9 明显升高的一个非常罕见的原因：胰高血糖素样肽-1 受体激动剂

目的胰高血糖素样肽-1（GLP-1）受体激动剂（GLP1-RAs）常用于治疗 2 型糖尿病（T2DM）。各种不良反应已逐渐见诸报端。本病例介绍了一种罕见的现象，即 GLP1-RA 导致碳水化合物抗原 19-9（CA 19-9）明显升高，但无肿瘤证据。方法采用混合方法，结合从定期门诊和随访中获得的病史，以及从实验室检查和影像学检查中获得的辅助检查。结论 GLP1-RA在治疗T2DM期间可能导致肿瘤标志物水平升高，因此有必要在治疗期间进行监测。应根据个人情况调整抗糖尿病治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & metabolism 医学-内分泌学与代谢

CiteScore

12.00

自引率

4.20%

发文量

审稿时长

13 days

期刊介绍： A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.